Lumasiran
Lumasiran
Lumasiran (pronounced loo-ma-si-ran) is a medication used in the treatment of primary hyperoxaluria type 1, a rare genetic disorder. It is an RNA interference (RNAi) drug developed by Alnylam Pharmaceuticals.
Etymology
The name "Lumasiran" is derived from the drug's mechanism of action. "Luma" is a reference to the luminescence of RNA, while "siran" is a reference to the silencing effect the drug has on the production of oxalate.
Mechanism of Action
Lumasiran works by targeting and reducing the levels of a specific enzyme, glycolate oxidase, in the liver. This enzyme is involved in the production of oxalate, a substance that can form crystals in the kidneys and urinary tract, leading to serious complications. By reducing the levels of this enzyme, Lumasiran can decrease the production of oxalate and prevent the formation of these harmful crystals.
Related Terms
- RNA interference: A biological process in which RNA molecules inhibit gene expression or translation, by neutralizing targeted mRNA molecules.
- Primary hyperoxaluria type 1: A rare genetic disorder characterized by the overproduction of a substance called oxalate.
- Glycolate oxidase: An enzyme involved in the production of oxalate.
- Alnylam Pharmaceuticals: A biopharmaceutical company that developed Lumasiran.
See Also
- Oxlumo: The brand name under which Lumasiran is marketed.
- RNAi therapeutics: A new class of drugs that use RNA interference to treat diseases.
External links
- Medical encyclopedia article on Lumasiran
- Wikipedia's article - Lumasiran
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski